Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors
Status:
Completed
Trial end date:
2014-06-01
Target enrollment:
Participant gender:
Summary
This is a Phase I, open-label, dose-escalation trial in patients with advanced/metastatic
solid tumors refractory to standard therapy; tumors may include malignant melanoma, non-small
cell lung cancer, renal cell carcinoma, and squamous cell carcinoma of the head and neck.
These tumor types were selected because evidence of biological activity was observed in these
tumor types in a Phase I study of JX-594 (Pexa-Vec) administered by intratumoral injection in
patients with metastatic disease to the liver. Patients will receive treatment at one of five
dose levels in a sequential dose-escalating design.